Numen CSO (YC S23) • Rice/Oxford Alum • Rhodes Scholar (Texas & Magdalen, 2016) • zipper club (Indiana & BAV, 2019)
San Francisco, CA
Joined July 2012
- Tweets432
- Following770
- Followers431
- Likes4.7K
Tom Carroll retweeted
Operable setting (2026): sciencedirect.com/science/ar…
Inoperable setting (2023): cell.com/cancer-cell/fulltex…
In this new work, we also establish a 5-gene signature C-FISH correlated with TMC to allow estimation of this parameter when bulk RNA-seq is not available. Happy reading!
Tom Carroll retweeted
🚨 New paper out: Tumor monocyte content predicts immunochemotherapy outcomes for operable esophageal cancer. Similar to our previous work in inoperable setting, high TMC is associated w/ longer OS. May help identify EAC patients likely to respond to neoadjuvant ICI. Links below:
🚨 New paper out: Tumor monocyte content predicts immunochemotherapy outcomes for operable esophageal cancer. Similar to our previous work in inoperable setting, high TMC is associated w/ longer OS. May help identify EAC patients likely to respond to neoadjuvant ICI. Links below:
Operable setting (2026): sciencedirect.com/science/ar…
Inoperable setting (2023): cell.com/cancer-cell/fulltex…
In this new work, we also establish a 5-gene signature C-FISH correlated with TMC to allow estimation of this parameter when bulk RNA-seq is not available. Happy reading!
Tom Carroll retweeted
The reason mRNA can't cure more diseases? Delivery.
We built NGX1 to deliver mRNA to any cell in the body using AI and multivalent physics.
Tom Carroll retweeted
Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. Full phase 3 KEYNOTE-B15/EV-304 trial results: nej.md/4wh8FB9
Editorial: A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era? nej.md/4b67lZi
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer." The graph shows event-free survival. The trial name, KEYNOTE-B15/EV-304, is in parentheses after the title. The NEJM identity sits at the bottom.
Tom Carroll retweeted
Truly monumental day for the #Ross community. Congratulations to trailblazers and colleagues @IHamamsy and @OuzounianMD for simultaneous publication of their incredible manuscripts reaffirming the magic of the Ross Procedure in @JACCJournals
Tom Carroll retweeted
🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!
AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
ir.revmed.com/news-releases/…
Tom Carroll retweeted
For the second year in a row, Parafilm has been recognized with the Nobel Prize in Chemistry 2025! 🏅
Tom Carroll retweeted
Delighted to share the final version of Richard Zhou's study on how the CD163 scavenger receptor cleans up after toxic haemoglobin spills out from our blood cells. An amazing grabber mechanism!
rdcu.be/ewPA2
Tom Carroll retweeted
Reminds me of one of the worst cases of scientific fraud ever:
>cardiologist fakes data showing better outcomes for patients who were given beta blockers before surgery
>Europe changes its medical guidelines based on this research
>turns out beta blockers increase risk of death by 27%
>might have killed up to 800,000 people
Great Q&A in Politico with James Heathers, who is leading the Medical Evidence Project to "find bad medical evidence before it kills people."
xitter.cf/Meaningness/status/193…
Tom Carroll retweeted
Check out what we're working on at Olio Labs!
70% of patients taking GLP-1's (like Ozempic) are women, but they experience >2x side effect rates than men.
What is driving this difference?
We combine human EMR data, mouse & rat behavior, and scRNAseq to figure it out:
Tom Carroll retweeted
Today we report in @NatureMedicine the development of a base editing strategy for prion disease, currently a fatal and rapidly progressing neurogenerative condition with no effective treatment. @PrionAlliance @DevermanLab (1/13)
drive.google.com/file/d/1DVp…
